Speaker: Dr. Anwar Ahmed and Dr. Kathleen Pratt
Register to join us and learn about race, ethnicity, F8 variants, and inhibitor risks, as well as an analysis of the "My Life of Our Future" hemophilia A database.
Description: Join us for an insightful webinar as we delve into the findings of our latest research project, "My Life of Our Future" hemophilia A database. In this session, our expert panel will analyze the complex interplay between race, ethnicity, F8 variants, and inhibitor risk in individuals with hemophilia A.
Through in-depth data analysis and case studies, we will explore the impact of genetic and demographic factors on inhibitor development and treatment outcomes. Our discussion will highlight key trends, disparities, and potential implications for personalized care and treatment strategies.
Whether you're a healthcare provider, researcher, or patient advocate, this webinar offers valuable insights into understanding and addressing the unique challenges faced by individuals with hemophilia A across different racial and ethnic backgrounds.
Don't miss this opportunity to gain valuable knowledge and contribute to the advancement of hemophilia care. Register now to secure your spot!
NBDF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn about the latest in research, breakthrough developments, and more.
Register for Wednesday Webinar Series
About Dr. Anwar Ahmed:
Dr. Ahmed is a faculty member in the Department of Preventive Medicine and Biostatistics at the Uniformed Services University of the Health Sciences, Bethesda, MD. Ahmed received his Ph.D. in Biostatistics from Virginia Commonwealth University (VCU) in 2010. He received his M.S. in Statistics from VCU in 2004 and a B.S. in Applied Statistics and Demography from the University of Gezira, Sudan, in 2001. His research focuses on the evaluation of clinical utilities of diagnostic tests and risk models.
About Dr. Kathleen Pratt:
Dr. Kathleen Pratt is Professor and Vice Chair for Research in the Department of Medicine, Uniformed Services University of the Health Sciences, in Bethesda, MD. As an undergraduate at the University of Washington in Seattle, WA, she worked as a technician in the laboratory of Prof. Earl Davie, acquiring a lifelong fascination with blood coagulation and hemostasis. She received a PhD in Biophysical Chemistry from Cornell University under the supervision of Prof Harold Scheraga and then returned to Earl Davie’s lab as a postdoctoral fellow.
There, she determined high-resolution crystal structures of recombinant fragments of fibrinogen and factor VIII (FVIII), and of a complex formed by the FVIII C2 domain and an inhibitory antibody. These structures elucidated the membrane binding mode of FVIII and one mechanism by which antibodies (“inhibitor responses”) can block the procoagulant activity of FVIII. Dr. Pratt then established an independent lab at the Puget Sound Blood Center Research Institute in Seattle, where she and her team further characterized both antibody and CD4 T-cell responses to FVIII. She moved to Bethesda in 2013, continuing her studies of T-cell responses, immune tolerance to FVIII, and the design of less immunogenic FVIII proteins. Recently, she and her colleague Dr. Anwar Ahmed carried out an in-depth analysis of the “My Life Our Future” database, focusing particularly on potential genetic risk factors for inhibitor development.